journal
https://read.qxmd.com/read/38608694/cabozantinib-monotherapy-for-advanced-adrenocortical-carcinoma-a-single-arm-phase-2-trial
#1
JOURNAL ARTICLE
Matthew T Campbell, Vania Balderrama-Brondani, Camilo Jimenez, Gina Tamsen, Leonardo P Marcal, Jeena Varghese, Amishi Y Shah, James P Long, Miao Zhang, Joshua Ochieng, Cara Haymaker, Mouhammed Amir Habra
BACKGROUND: Adrenocortical carcinoma is a rare malignancy with poor response to systemic chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma. Cabozantinib is a multikinase inhibitor approved in multiple malignancies. This is the first prospective trial to explore the anti-tumour activity, safety, and pharmacokinetic profile of cabozantinib in patients with advanced adrenocortical carcinoma. METHODS: This investigator-initiated, single-arm, phase 2 trial in adult patients (aged ≥18 years) with advanced adrenocortical carcinoma was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA)...
April 9, 2024: Lancet Oncology
https://read.qxmd.com/read/38608693/cabozantinib-in-patients-with-unresectable-and-progressive-metastatic-phaeochromocytoma-or-paraganglioma-the-natalie-trial-a-single-arm-phase-2-trial
#2
JOURNAL ARTICLE
Camilo Jimenez, Mouhammed Amir Habra, Matthew T Campbell, Gina Tamsen, Damaris Cruz-Goldberg, James Long, Roland Bassett, Robert Dantzer, Vania Balderrama-Brondani, Jeena Varghese, Yang Lu
BACKGROUND: Metastatic phaeochromocytomas and paragangliomas (MPPGs) are orphan diseases. Up to 50% of MPPGs are associated with germline pathogenic variants of the SDHB gene. These tumours and many non-familial MPPGs exhibit a phenotype that is characterised by abnormal angiogenesis. We aimed to assess the activity and safety of cabozantinib, an antiangiogenic multi-tyrosine kinase inhibitor, in patients with MPPGs. METHODS: The Natalie Trial is a single-arm, phase 2 clinical trial being conducted at The University of Texas MD Anderson Cancer Center (Houston, TX, USA)...
April 9, 2024: Lancet Oncology
https://read.qxmd.com/read/38608692/mitotane-a-friend-or-a-foe-before-cabozantinib-treatment-in-adrenocortical-cancer
#3
JOURNAL ARTICLE
Margaret E Wierman
No abstract text is available yet for this article.
April 9, 2024: Lancet Oncology
https://read.qxmd.com/read/38608691/nivolumab-with-or-without-ipilimumab-in-patients-with-recurrent-or-metastatic-cervical-cancer-checkmate-358-a-phase-1-2-open-label-multicohort-trial
#4
JOURNAL ARTICLE
Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese, Asim Amin, Christopher D Lao, Valentina Boni, William H Sharfman, Jong Chul Park, Makoto Tahara, Suzanne L Topalian, Manuel Magallanes, Alejandro Molina Alavez, Tariq Aziz Khan, Catherine Copigneaux, Michelle Lee, Charlie Garnett-Benson, Xuya Wang, R Wendel Naumann
BACKGROUND: In preliminary findings from the recurrent or metastatic cervical cancer cohort of CheckMate 358, nivolumab showed durable anti-tumour responses, and the combination of nivolumab plus ipilimumab showed promising clinical activity. Here, we report long-term outcomes from this cohort. METHODS: CheckMate 358 was a phase 1-2, open-label, multicohort trial. The metastatic cervical cancer cohort enrolled patients from 30 hospitals and cancer centres across ten countries...
April 9, 2024: Lancet Oncology
https://read.qxmd.com/read/38588682/mri-guided-optimisation-of-neoadjuvant-chemotherapy-duration-in-stage-ii-iii-her2-positive-breast-cancer-train-3-a-multicentre-single-arm-phase-2-study
#5
JOURNAL ARTICLE
Anna van der Voort, Fleur M Louis, Mette S van Ramshorst, Rob Kessels, Ingrid A Mandjes, Inge Kemper, Mariette J Agterof, Wim A van der Steeg, Joan B Heijns, Marlies L van Bekkum, Ester J Siemerink, Philomeen M Kuijer, Astrid Scholten, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Ritse M Mann, Gabe S Sonke
BACKGROUND: Patients with stage II-III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. Although increasing the number of chemotherapy cycles improves pathological complete response rates, early complete responses are common. We investigated whether the duration of chemotherapy could be tailored on the basis of radiological response. METHODS: TRAIN-3 is a single-arm, phase 2 study in 43 hospitals in the Netherlands...
April 5, 2024: Lancet Oncology
https://read.qxmd.com/read/38588681/expansion-of-radiotherapy-access-in-ethiopia
#6
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
April 5, 2024: Lancet Oncology
https://read.qxmd.com/read/38561010/pembrolizumab-plus-concurrent-chemoradiotherapy-versus-placebo-plus-concurrent-chemoradiotherapy-in-patients-with-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-keynote-412-a-randomised-double-blind-phase-3-trial
#7
JOURNAL ARTICLE
Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo Alves, Iane Pinto Figueiredo Lima, Brett G M Hughes, Yoann Pointreau, Sercan Aksoy, Simon Laban, Richard Greil, Martin Burian, Marcin Hetnał, Jean-Pierre Delord, Ricard Mesía, Miren Taberna, John N Waldron, Christian Simon, Vincent Grégoire, Kevin J Harrington, Ramona F Swaby, Yayan Zhang, Burak Gumuscu, Behzad Bidadi, Lillian L Siu
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC. METHODS: In the randomised, double-blind, phase 3 KEYNOTE-412 trial, participants with newly diagnosed, high-risk, unresected locally advanced HNSCC from 130 medical centres globally were randomly assigned (1:1) to pembrolizumab (200 mg) plus chemoradiotherapy or placebo plus chemoradiotherapy...
March 29, 2024: Lancet Oncology
https://read.qxmd.com/read/38555932/uk-tobacco-and-vapes-bill-one-step-closer
#8
JOURNAL ARTICLE
Priya Venkatesan
No abstract text is available yet for this article.
March 28, 2024: Lancet Oncology
https://read.qxmd.com/read/38555931/sso-2024
#9
JOURNAL ARTICLE
Allison Landman
No abstract text is available yet for this article.
March 28, 2024: Lancet Oncology
https://read.qxmd.com/read/38555930/environmental-pollution-and-cancer-risk-in-la-oraya-peru
#10
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
March 28, 2024: Lancet Oncology
https://read.qxmd.com/read/38552658/clinical-and-biological-landscape-of-constitutional-mismatch-repair-deficiency-syndrome-an-international-replication-repair-deficiency-consortium-cohort-study
#11
JOURNAL ARTICLE
Ayse Bahar Ercan, Melyssa Aronson, Nicholas R Fernandez, Yuan Chang, Adrian Levine, Zhihui Amy Liu, Logine Negm, Melissa Edwards, Vanessa Bianchi, Lucie Stengs, Jiil Chung, Abeer Al-Battashi, Agnes Reschke, Alex Lion, Alia Ahmad, Alvaro Lassaletta, Alyssa T Reddy, Amir F Al-Darraji, Amish C Shah, An Van Damme, Anne Bendel, Aqeela Rashid, Ashley S Margol, Bethany L Kelly, Bojana Pencheva, Brandie Heald, Brianna Lemieux-Anglin, Bruce Crooks, Carl Koschmann, Catherine Gilpin, Christopher C Porter, David Gass, David Samuel, David S Ziegler, Deborah T Blumenthal, Dennis John Kuo, Dima Hamideh, Donald Basel, Dong-Anh Khuong-Quang, Duncan Stearns, Enrico Opocher, Fernando Carceller, Hagit Baris Feldman, Helen Toledano, Ira Winer, Isabelle Scheers, Ivana Fedorakova, Jack M Su, Jaime Vengoechea, Jaroslav Sterba, Jeffrey Knipstein, Jordan R Hansford, Julieta Rita Gonzales-Santos, Kanika Bhatia, Kevin J Bielamowicz, Khurram Minhas, Kim E Nichols, Kristina A Cole, Lynette Penney, Magnus Aasved Hjort, Magnus Sabel, Maria Joao Gil-da-Costa, Matthew J Murray, Matthew Miller, Maude L Blundell, Maura Massimino, Maysa Al-Hussaini, Mazin F Al-Jadiry, Melanie A Comito, Michael Osborn, Michael P Link, Michal Zapotocky, Mithra Ghalibafian, Najma Shaheen, Naureen Mushtaq, Nicolas Waespe, Nobuko Hijiya, Noemi Fuentes-Bolanos, Olfat Ahmad, Omar Chamdine, Paromita Roy, Pavel N Pichurin, Per Nyman, Rachel Pearlman, Rebecca C Auer, Reghu K Sukumaran, Rejin Kebudi, Rina Dvir, Robert Raphael, Ronit Elhasid, Rose B McGee, Rose Chami, Ryan Noss, Ryuma Tanaka, Salmo Raskin, Santanu Sen, Scott Lindhorst, Sebastien Perreault, Shani Caspi, Shazia Riaz, Shlomi Constantini, Sophie Albert, Stanley Chaleff, Stefan Bielack, Stefano Chiaravalli, Stuart Louis Cramer, Sumita Roy, Suzanne Cahn, Suzanne Penna, Syed Ahmer Hamid, Tariq Ghafoor, Uzma Imam, Valerie Larouche, Vanan Magimairajan Issai, William D Foulkes, Yi Yen Lee, Paul C Nathan, Yosef E Maruvka, Mary-Louise C Greer, Carol Durno, Adam Shlien, Birgit Ertl-Wagner, Anita Villani, David Malkin, Cynthia Hawkins, Eric Bouffet, Anirban Das, Uri Tabori
BACKGROUND: Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare and aggressive cancer predisposition syndrome. Because a scarcity of data on this condition contributes to management challenges and poor outcomes, we aimed to describe the clinical spectrum, cancer biology, and impact of genetics on patient survival in CMMRD. METHODS: In this cohort study, we collected cross-sectional and longitudinal data on all patients with CMMRD, with no age limits, registered with the International Replication Repair Deficiency Consortium (IRRDC) across more than 50 countries...
March 26, 2024: Lancet Oncology
https://read.qxmd.com/read/38522454/arsenic-contamination-and-cancer-risk-in-bangladesh
#12
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
March 21, 2024: Lancet Oncology
https://read.qxmd.com/read/38522453/1-in-9-usa-cancer-diagnoses-missed-during-2020-covid-19-pandemic
#13
JOURNAL ARTICLE
Tony Kirby
No abstract text is available yet for this article.
March 21, 2024: Lancet Oncology
https://read.qxmd.com/read/38522452/epa-ruling-to-ban-chrysotile-asbestos
#14
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
March 21, 2024: Lancet Oncology
https://read.qxmd.com/read/38493789/massive-us-cybersecurity-breach-highlights-perils-of-health-care-consolidation
#15
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
March 14, 2024: Lancet Oncology
https://read.qxmd.com/read/38467131/activity-of-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-analysis-of-the-venice-1-multicentre-open-label-single-arm-phase-3b-trial
#16
JOURNAL ARTICLE
Arnon P Kater, Önder Arslan, Fatih Demirkan, Yair Herishanu, Burhan Ferhanoglu, Marcos Gonzalez Diaz, Brian Leber, Marco Montillo, Panayiotis Panayiotidis, Davide Rossi, Alan Skarbnik, Adrian Tempescul, Mehmet Turgut, Clemens H Mellink, Anne-Marie F van der Kevie-Kersemaekers, Stuart Lanham, Ben Sale, Luis Del Rio, Relja Popovic, Brenda J Chyla, Todd Busman, Viktor Komlosi, Xifeng Wang, Kavita Sail, German E Pena, Tamas Vizkelety, Francesco Forconi
BACKGROUND: Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in the relapsed setting is unknown. We aimed to assess venetoclax activity in patients with or without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment. METHODS: This multicentre, open-label, single-arm, phase 3b trial (VENICE-1) assessed activity and safety of venetoclax monotherapy in adults with relapsed or refractory chronic lymphocytic leukaemia, stratified by previous exposure to a BCRi...
March 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38461834/alabama-supreme-court-s-extrauterine-children-decision-alarms-oncologists-and-fertility-experts
#17
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
March 7, 2024: Lancet Oncology
https://read.qxmd.com/read/38461833/innovation-in-gynaecological-cancer-highlighting-global-disparities
#18
JOURNAL ARTICLE
Maria Kyrgiou, Sarah Bowden, Lynette Denny, Anna Fagotti, Nadim R Abu-Rustum, Pedro T Ramirez, Denis Querleu
No abstract text is available yet for this article.
March 7, 2024: Lancet Oncology
https://read.qxmd.com/read/38461832/non-communicable-diseases-in-humanitarian-settings
#19
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
March 7, 2024: Lancet Oncology
https://read.qxmd.com/read/38432235/indonesia-and-the-philippines-take-steps-to-control-cancer
#20
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
February 29, 2024: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.